2 474

Cited 16 times in

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial

Authors
 Jaeheon Jeong  ;  Byoung Chul Cho  ;  Joo Hyuk Sohn  ;  Hye Jin Choi  ;  Se Hyun Kim  ;  Young Joo Lee  ;  Min Kyu Jung  ;  Sang Joon Shin  ;  Moo-Suk Park  ;  Se Kyu Kim  ;  Joon Chang  ;  Joo Hang Kim 
Citation
 LUNG CANCER, Vol.70(1) : 77-81, 2010 
Journal Title
LUNG CANCER
ISSN
 0169-5002 
Issue Date
2010
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives* ; Camptothecin/therapeutic use ; Carcinoma, Small Cell/drug therapy* ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/drug therapy* ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Salvage Therapy ; Topoisomerase I Inhibitors/adverse effects ; Topoisomerase I Inhibitors/therapeutic use*
Keywords
Belotecan ; SCLC ; Topoisomerase I inhibitor
Abstract
BACKGROUND: Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure.

PATIENTS AND METHODS: SCLC patients, who had relapsed at least 3 months after achieving objective response to irinotecan plus platinum chemotherapy, were eligible. Belotecan was administered at a dose of 0.5 mg/m(2)/day for 5 consecutive days every 3 weeks.

RESULTS: Twenty-seven patients were enrolled in this study. Twenty-five patients were evaluated for response, and 27 patients were evaluated for toxicity and survival. The overall response rate was 22%. The median time to progression was 4.7 months (95% CI, 3.6-5.8 months), and the median overall survival was 13.1 months (95% CI, 10.4-15.8 months). The most frequent grade 3/4 toxicities were neutropenia (93%) and thrombocytopenia (48%). There was one treatment-related death due to pneumonia.

CONCLUSION: Belotecan showed modest activity and manageable toxicities in relapsing SCLC patients in this study which was conducted in Asia. But further study in Caucasian patients is needed.
Full Text
http://www.sciencedirect.com/science/article/pii/S0169500210000085
DOI
10.1016/j.lungcan.2010.01.006
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Se Hyun(김세현)
Kim, Joo Hang(김주항)
Park, Moo Suk(박무석) ORCID logo https://orcid.org/0000-0003-0820-7615
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Jung, Jae Hun(정재헌)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/101981
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links